AR045811A1 - 5- arilpirimidinas como agentes ainticancerigenos - Google Patents

5- arilpirimidinas como agentes ainticancerigenos

Info

Publication number
AR045811A1
AR045811A1 ARP040103441A ARP040103441A AR045811A1 AR 045811 A1 AR045811 A1 AR 045811A1 AR P040103441 A ARP040103441 A AR P040103441A AR P040103441 A ARP040103441 A AR P040103441A AR 045811 A1 AR045811 A1 AR 045811A1
Authority
AR
Argentina
Prior art keywords
alkyl
mammal
compounds
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
ARP040103441A
Other languages
English (en)
Spanish (es)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR045811A1 publication Critical patent/AR045811A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ARP040103441A 2003-09-24 2004-09-23 5- arilpirimidinas como agentes ainticancerigenos AR045811A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US50548703P 2003-09-24 2003-09-24

Publications (1)

Publication Number Publication Date
AR045811A1 true AR045811A1 (es) 2005-11-16

Family

ID=34393022

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040103441A AR045811A1 (es) 2003-09-24 2004-09-23 5- arilpirimidinas como agentes ainticancerigenos

Country Status (24)

Country Link
US (1) US7524849B2 (cg-RX-API-DMAC7.html)
EP (1) EP1663241B1 (cg-RX-API-DMAC7.html)
JP (1) JP2007506746A (cg-RX-API-DMAC7.html)
KR (1) KR20060089215A (cg-RX-API-DMAC7.html)
CN (1) CN1871009A (cg-RX-API-DMAC7.html)
AR (1) AR045811A1 (cg-RX-API-DMAC7.html)
AT (1) ATE432077T1 (cg-RX-API-DMAC7.html)
AU (1) AU2004275733A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0414736A (cg-RX-API-DMAC7.html)
CA (1) CA2539235A1 (cg-RX-API-DMAC7.html)
CO (1) CO5690592A2 (cg-RX-API-DMAC7.html)
DE (1) DE602004021269D1 (cg-RX-API-DMAC7.html)
EC (1) ECSP066457A (cg-RX-API-DMAC7.html)
GT (1) GT200400188A (cg-RX-API-DMAC7.html)
IL (1) IL174305A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA06003207A (cg-RX-API-DMAC7.html)
NO (1) NO20061319L (cg-RX-API-DMAC7.html)
PA (1) PA8613201A1 (cg-RX-API-DMAC7.html)
PE (1) PE20050470A1 (cg-RX-API-DMAC7.html)
RU (1) RU2006107578A (cg-RX-API-DMAC7.html)
SA (1) SA04250303A (cg-RX-API-DMAC7.html)
TW (1) TW200512198A (cg-RX-API-DMAC7.html)
WO (1) WO2005030216A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200602386B (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200637556A (en) * 2005-01-31 2006-11-01 Basf Ag Substituted 5-phenyl pyrimidines I in therapy
JP2008543838A (ja) * 2005-06-13 2008-12-04 ワイス チューブリンインヒビターおよびその調製のためのプロセス
CN101193884A (zh) 2005-06-13 2008-06-04 惠氏公司 微管蛋白抑制剂和其制备方法
US20110201496A1 (en) * 2006-03-27 2011-08-18 Joachim Rheinheimer Substituted 5-Hetaryl-4-Aminopyrimidines
CL2007002231A1 (es) * 2006-08-02 2008-04-11 Basf Ag Uso de compuestos derivados de 5-(het) arilpirimidina para combatir hongos daninos; compuestos derivados de 5-(het) arilpirimidina; agente fungicida; y agente farmaceutico.
WO2008084081A2 (en) * 2007-01-11 2008-07-17 Basf Se 2-substituted 5-phenylpyrimidines for the treatment of proliferative disorders
WO2009007187A1 (de) * 2007-07-09 2009-01-15 Basf Se Substituierte 5-hetarylpyrimidine
HUE064883T2 (hu) 2011-04-22 2024-04-28 Signal Pharm Llc Szubsztituált diaminokarboxamid- és diaminokarbonitril-pirimidinek, azok készítményei és azokkal történõ kezelési eljárások
WO2014047257A2 (en) 2012-09-19 2014-03-27 The Trustees Of The University Of Pennsylvania Heterocyclic compounds and their use for the treatment of neurodegenerative tauopathies
NZ715903A (en) 2014-01-30 2017-06-30 Signal Pharm Llc Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
KR102606253B1 (ko) 2014-12-16 2023-11-27 시그날 파마소티칼 엘엘씨 2-(tert-부틸아미노)-4-((1r,3r,4r)-3-하이드록시-4-메틸사이클로헥실아미노)-피리미딘-5-카복사마이드의 제형
US9513297B2 (en) 2014-12-16 2016-12-06 Signal Pharmaceuticals, Llc Methods for measurement of inhibition of c-Jun N-terminal kinase in skin
CA2975260C (en) 2015-01-29 2024-05-21 Signal Pharmaceuticals Llc Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
WO2017019487A1 (en) 2015-07-24 2017-02-02 Celgene Corporation Methods of synthesis of (1r,2r,5r)-5-amino-2-methylcyclohexanol hydrochloride and intermediates useful therein
US11623927B2 (en) 2018-03-02 2023-04-11 The Trustees Of The University Of Pennsylvania Substituted [1,2,4]triazolo[1,5-a]pyrimidines for stabilizing microtubules
WO2021085540A1 (ja) * 2019-11-01 2021-05-06 ユニマテック株式会社 含フッ素ピリミジン化合物およびその製造方法
TW202132285A (zh) * 2019-11-13 2021-09-01 美商愛彼特生物製藥股份有限公司 經取代異吲哚啉基2,2’-聯嘧啶基化合物、其類似物及使用其之方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US88096A (en) * 1869-03-23 t h a y e r
US69242A (en) * 1867-09-24 Calvin pepper
US61889A (en) * 1867-02-05 Improvement in animal teaps
US147744A (en) * 1874-02-24 Improvement in locomotive-furnaces
US116429A (en) * 1871-06-27 Improvement in dial-telegraph apparatus
GB9700664D0 (en) 1997-01-14 1997-03-05 British Tech Group Anti-cancer agents
US6117876A (en) 1997-04-14 2000-09-12 American Cyanamid Company Fungicidal trifluorophenyl-triazolopyrimidines
EP1076053B1 (en) 1998-04-27 2006-11-29 Kumiai Chemical Industry Co., Ltd. 3-arylphenyl sulfide derivatives and insecticides and miticides
US5986135A (en) 1998-09-25 1999-11-16 American Cyanamid Company Fungicidal trifluoromethylalkylamino-triazolopyrimidines
US6156925A (en) 1998-09-25 2000-12-05 American Cyanamid Company Process for the preparation of halogenated phenylmaloates
ES2246330T3 (es) 2000-06-13 2006-02-16 Basf Aktiengesellschaft 2-(cianoamino)pirimidinas 5-fenil-sustituidas fungicidas.
US6670362B2 (en) 2000-09-20 2003-12-30 Pfizer Inc. Pyridazine endothelin antagonists
BR0207975A (pt) * 2001-03-15 2004-06-15 Basf Ag Composto, processo para preparar 5 fenilpiridinas, produto intermediário, agente adequado para combater fungos nocivos fitopatogênicos, e, processo para combater fungos nocivos fitopatogênicos
ES2242839T3 (es) 2001-04-20 2005-11-16 Ciba Specialty Chemicals Holding Inc. 4-amino-2- (piridin-2-il)pirimidina como sustancias activas microbicidas.
US7465735B2 (en) 2001-11-19 2008-12-16 Basf Aktiengesellschaft 5-Phenypyrimidines their preparation compositions comprising them and their use
EP1504001B1 (de) 2002-02-21 2009-04-15 Basf Se 2-(2-pyridyl)-5-phenyl-6-aminopyrimidine, verfahren und zwischenprodukte zu ihrer herstellung und ihre verwendung zur bekämpfung von schadpilzen
DE60314730T2 (de) 2002-03-15 2008-06-05 Ciba Specialty Chemicals Holding Inc. Verwendung von 4-aminopyrimidinen zur antimikrobiellen behandlung von oberflächen
WO2004048365A1 (en) 2002-11-21 2004-06-10 Chiron Corporation 2,4,6-trisubstituted pyrimidines as phosphotidylinositol (pi) 3-kinase inhibitors and their use in the treatment of cancer

Also Published As

Publication number Publication date
AU2004275733A1 (en) 2005-04-07
SA04250303A (ar) 2005-12-03
WO2005030216A1 (en) 2005-04-07
NO20061319L (no) 2006-04-20
ZA200602386B (en) 2009-03-25
CA2539235A1 (en) 2005-04-07
CN1871009A (zh) 2006-11-29
US7524849B2 (en) 2009-04-28
EP1663241B1 (en) 2009-05-27
IL174305A0 (en) 2008-02-09
US20050075357A1 (en) 2005-04-07
ECSP066457A (es) 2006-09-18
PE20050470A1 (es) 2005-10-03
MXPA06003207A (es) 2006-06-23
TW200512198A (en) 2005-04-01
RU2006107578A (ru) 2007-10-27
GT200400188A (es) 2005-05-02
DE602004021269D1 (de) 2009-07-09
ATE432077T1 (de) 2009-06-15
CO5690592A2 (es) 2006-10-31
BRPI0414736A (pt) 2006-11-21
KR20060089215A (ko) 2006-08-08
EP1663241A1 (en) 2006-06-07
PA8613201A1 (es) 2005-11-25
JP2007506746A (ja) 2007-03-22

Similar Documents

Publication Publication Date Title
AR045811A1 (es) 5- arilpirimidinas como agentes ainticancerigenos
JP2008535902A5 (cg-RX-API-DMAC7.html)
MX2023006145A (es) Inhibidores de prmt5 novedosos.
IL261852A (en) Substituted imidazole based compounds for treatment of cancer
RU2015143542A (ru) Ингибиторы jak2 и alk2 и способы их использования
MY206521A (en) Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
JP2008535903A5 (cg-RX-API-DMAC7.html)
RU2016118753A (ru) Производные пиридилкетона, способ их получения и их фармацевтическое применение
EA201991894A1 (ru) ПИПЕРИДИН-ЗАМЕЩЕННЫЕ ИНГИБИТОРЫ Mnk И СВЯЗАННЫЕ С НИМИ СПОСОБЫ
RU2014115847A (ru) Пирролопиримидиновые соединения для лечения злокачественной опухоли
JP2014503567A5 (cg-RX-API-DMAC7.html)
RU2011124304A (ru) Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе
RU2011150250A (ru) Антагонисты пути hedgehog и их терапевтическое применение
RU2013112871A (ru) Соединения для лечения рака
JP2013538213A5 (cg-RX-API-DMAC7.html)
CA2626032A1 (en) Camptothecin derivatives as chemoradiosensitizing agents
CN110769837A (zh) 与五氮杂大环状环配合物的联合癌症免疫疗法
RU2016138676A (ru) Ингибиторы усилителя zeste гомолога 2
CY1123161T1 (el) Παραγωγα δι(φαινυλοπροπανοειδους) γλυκερολης για τη θεραπεια του καρκινου
RU2013136861A (ru) Новое производное индола или индазола или его соль
IS5588A (is) Æxliseyðandi miðlar
JP2017503753A5 (cg-RX-API-DMAC7.html)
EA200701780A1 (ru) Противоопухолевое средство
TW200512211A (en) 6-[(substituted)phenyl]triazolopyrimidines as anticancer agents
WO2016205460A4 (en) Polycyclic derivatives targeting ral gtpases and their therapeutical applications

Legal Events

Date Code Title Description
FA Abandonment or withdrawal